Latuda, Other Generics Cleared In 2022 Helped Generate Nearly $19bn In Savings, US FDA Says

 
• By Derrick Gingery
  
One generic generated more than $4bn in savings in the year after its 2022 approval. (Shutterstock)

More from Generics

More from Market Access